Transanal mesorectal excision: early outcomes in Australia and New Zealand.


Journal

The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553

Informations de publication

Date de publication:
12 03 2021
Historique:
received: 08 07 2020
revised: 22 10 2020
accepted: 24 10 2020
entrez: 12 3 2021
pubmed: 13 3 2021
medline: 29 4 2021
Statut: ppublish

Résumé

Transanal total mesorectal excision (taTME) aims to overcome some of the technical challenges faced when operating on mid and low rectal cancers. Specimen quality has been confirmed previously, but recent concerns have been raised about oncological safety. This multicentre prospective study aimed to evaluate the safety of taTME among early adopters in Australia and New Zealand. Data from all consecutive patients who had taTME for rectal cancer from July 2014 to February 2020 at six tertiary referral centres in Australasia were recorded and analysed. A total of 308 patients of median age of 64 years underwent taTME. Some 75.6 per cent of patients were men, and the median BMI was 26.8 kg/m2. The median distance of tumour from anal verge was 7 cm. Neoadjuvant chemoradiotherapy was administered to 57.8 per cent of patients. The anastomotic leak rate was 8.1 per cent and there was no mortality within 30 days of surgery. Pathological examination found a complete mesorectum in 295 patients (95.8 per cent), a near-complete mesorectum in seven patients (2.3 per cent), and an incomplete mesorectum in six patients (1.9 per cent). The circumferential resection margin and distal resection margin was involved in nine patients (2.9 per cent), and two patients (0.6 per cent) respectively. Over a median follow-up of 22 months, the local recurrence rate was 1.9 per cent and median time to local recurrence was 30.5 months. This study showed that, with appropriate training and supervision, skilled minimally invasive rectal cancer surgeons can perform taTME with similar pathological and oncological results to open and laparoscopic surgery.

Sections du résumé

BACKGROUND
Transanal total mesorectal excision (taTME) aims to overcome some of the technical challenges faced when operating on mid and low rectal cancers. Specimen quality has been confirmed previously, but recent concerns have been raised about oncological safety. This multicentre prospective study aimed to evaluate the safety of taTME among early adopters in Australia and New Zealand.
METHODS
Data from all consecutive patients who had taTME for rectal cancer from July 2014 to February 2020 at six tertiary referral centres in Australasia were recorded and analysed.
RESULTS
A total of 308 patients of median age of 64 years underwent taTME. Some 75.6 per cent of patients were men, and the median BMI was 26.8 kg/m2. The median distance of tumour from anal verge was 7 cm. Neoadjuvant chemoradiotherapy was administered to 57.8 per cent of patients. The anastomotic leak rate was 8.1 per cent and there was no mortality within 30 days of surgery. Pathological examination found a complete mesorectum in 295 patients (95.8 per cent), a near-complete mesorectum in seven patients (2.3 per cent), and an incomplete mesorectum in six patients (1.9 per cent). The circumferential resection margin and distal resection margin was involved in nine patients (2.9 per cent), and two patients (0.6 per cent) respectively. Over a median follow-up of 22 months, the local recurrence rate was 1.9 per cent and median time to local recurrence was 30.5 months.
CONCLUSION
This study showed that, with appropriate training and supervision, skilled minimally invasive rectal cancer surgeons can perform taTME with similar pathological and oncological results to open and laparoscopic surgery.

Identifiants

pubmed: 33711138
pii: 6076623
doi: 10.1093/bjs/znaa098
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

214-219

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

S Lau (S)

Department of Surgery, University Hospital Geelong, Geelong, Victoria, Australia.

J Kong (J)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

S Bell (S)

Department of Surgery, Alfred Hospital, Melbourne, Victoria, Australia.

A Heriot (A)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

A Stevenson (A)

Department of Surgery, Royal Brisbane Hospital, Herston, Queensland, Australia.

J Moloney (J)

Department of Surgery, Royal Brisbane Hospital, Herston, Queensland, Australia.

J Hayes (J)

Department of Surgery, Auckland City Hospital, Auckland, New Zealand.

A Merrie (A)

Department of Surgery, Auckland City Hospital, Auckland, New Zealand.

T Eglinton (T)

Department of Surgery, University of Otago, Christchurch, New Zealand.

G Guest (G)

Department of Surgery, University Hospital Geelong, Geelong, Victoria, Australia.

D Clark (D)

Department of Surgery, Royal Brisbane Hospital, Herston, Queensland, Australia.

S Warrier (S)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Department of Surgery, Alfred Hospital, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH